VGX International announces IND filing of VGX-1027

VGX International announced on December 20 that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-1027 in healthy volunteers.

VGX-1027 is the company's lead drug candidate for the treatment of rheumatoid arthritis and type 1 diabetes. It is a novel orally-active, small-molecule compound with broad...